Celldex Therapeutics (NASDAQ:CLDX) Price Target Raised to $100.00

Celldex Therapeutics (NASDAQ:CLDX) had its price objective raised by research analysts at Guggenheim from $90.00 to $100.00 in a note issued to investors on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Guggenheim’s price objective suggests a potential upside of 182.89% from the stock’s previous close.

CLDX has been the topic of several other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Celldex Therapeutics in a research report on Friday. Wells Fargo & Company upped their price target on Celldex Therapeutics from $38.00 to $54.00 and gave the company an “overweight” rating in a research report on Wednesday, May 13th. Wall Street Zen upgraded Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, July 12th. Wolfe Research upgraded Celldex Therapeutics from a “peer perform” rating to an “outperform” rating and set a $44.00 target price on the stock in a report on Monday, March 23rd. Finally, UBS Group increased their target price on shares of Celldex Therapeutics from $38.00 to $45.00 and gave the company a “buy” rating in a research report on Wednesday, June 10th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $53.91.

Celldex Therapeutics Price Performance

NASDAQ CLDX opened at $35.35 on Monday. Celldex Therapeutics has a fifty-two week low of $19.72 and a fifty-two week high of $40.30. The business has a fifty day moving average price of $33.32 and a two-hundred day moving average price of $30.41. The stock has a market capitalization of $2.77 billion, a PE ratio of -8.30 and a beta of 0.90.

Celldex Therapeutics (NASDAQ:CLDX) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.03). The business had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.80 million. As a group, sell-side analysts expect that Celldex Therapeutics will post -4.36 earnings per share for the current year.

Institutional Investors Weigh In On Celldex Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in CLDX. Wellington Management Group LLP grew its stake in Celldex Therapeutics by 39.3% during the fourth quarter. Wellington Management Group LLP now owns 8,079,608 shares of the biopharmaceutical company’s stock worth $219,442,000 after purchasing an additional 2,279,605 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Celldex Therapeutics by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 4,027,407 shares of the biopharmaceutical company’s stock worth $109,384,000 after buying an additional 72,817 shares in the last quarter. Bellevue Group AG boosted its holdings in shares of Celldex Therapeutics by 7.6% during the 3rd quarter. Bellevue Group AG now owns 3,557,669 shares of the biopharmaceutical company’s stock worth $92,037,000 after buying an additional 250,100 shares in the last quarter. Commodore Capital LP grew its position in shares of Celldex Therapeutics by 7.8% during the 2nd quarter. Commodore Capital LP now owns 3,450,000 shares of the biopharmaceutical company’s stock worth $70,208,000 after buying an additional 250,000 shares during the period. Finally, State Street Corp grew its position in shares of Celldex Therapeutics by 19.5% during the 4th quarter. State Street Corp now owns 3,397,713 shares of the biopharmaceutical company’s stock worth $92,282,000 after buying an additional 555,579 shares during the period.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.